176 related articles for article (PubMed ID: 20007548)
1. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome.
Ng AP; Hyland CD; Metcalf D; Carmichael CL; Loughran SJ; Di Rago L; Kile BT; Alexander WS
Blood; 2010 May; 115(19):3966-9. PubMed ID: 20007548
[TBL] [Abstract][Full Text] [Related]
2. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
[TBL] [Abstract][Full Text] [Related]
3. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.
Kirsammer G; Jilani S; Liu H; Davis E; Gurbuxani S; Le Beau MM; Crispino JD
Blood; 2008 Jan; 111(2):767-75. PubMed ID: 17901249
[TBL] [Abstract][Full Text] [Related]
4. Transient myeloproliferative disorder with partial trisomy 21.
Takahashi T; Inoue A; Yoshimoto J; Kanamitsu K; Taki T; Imada M; Yamada M; Ninomiya S; Toki T; Terui K; Ito E; Shimada A
Pediatr Blood Cancer; 2015 Nov; 62(11):2021-4. PubMed ID: 26138905
[TBL] [Abstract][Full Text] [Related]
5. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.
Birger Y; Goldberg L; Chlon TM; Goldenson B; Muler I; Schiby G; Jacob-Hirsch J; Rechavi G; Crispino JD; Izraeli S
Blood; 2013 Aug; 122(6):988-98. PubMed ID: 23719302
[TBL] [Abstract][Full Text] [Related]
6. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
7. The proto-oncogene ERG in megakaryoblastic leukemias.
Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
[TBL] [Abstract][Full Text] [Related]
8. Perturbation of the immune cells and prenatal neurogenesis by the triplication of the Erg gene in mouse models of Down syndrome.
Ishihara K; Shimizu R; Takata K; Kawashita E; Amano K; Shimohata A; Low D; Nabe T; Sago H; Alexander WS; Ginhoux F; Yamakawa K; Akiba S
Brain Pathol; 2020 Jan; 30(1):75-91. PubMed ID: 31206867
[TBL] [Abstract][Full Text] [Related]
9. Segmental trisomy as a mouse model for Down syndrome.
Davisson MT; Schmidt C; Reeves RH; Irving NG; Akeson EC; Harris BS; Bronson RT
Prog Clin Biol Res; 1993; 384():117-33. PubMed ID: 8115398
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights into Down syndrome-associated leukemia.
Vyas P; Crispino JD
Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
[TBL] [Abstract][Full Text] [Related]
11. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.
Reynolds LE; Watson AR; Baker M; Jones TA; D'Amico G; Robinson SD; Joffre C; Garrido-Urbani S; Rodriguez-Manzaneque JC; Martino-Echarri E; Aurrand-Lions M; Sheer D; Dagna-Bricarelli F; Nizetic D; McCabe CJ; Turnell AS; Kermorgant S; Imhof BA; Adams R; Fisher EM; Tybulewicz VL; Hart IR; Hodivala-Dilke KM
Nature; 2010 Jun; 465(7299):813-7. PubMed ID: 20535211
[TBL] [Abstract][Full Text] [Related]
12. [Is Neuron-Vascular Communication Disturbed in the Delayed Prenatal Brain Development of a Mouse Model of Down Syndrome?].
Ishihara K
Yakugaku Zasshi; 2021; 141(3):369-373. PubMed ID: 33642505
[TBL] [Abstract][Full Text] [Related]
13. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
14. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation.
Magalhães IQ; Splendore A; Emerenciano M; Córdoba MS; Córdoba JC; Allemand PA; Ferrari I; Pombo-de-Oliveira MS
J Pediatr Hematol Oncol; 2005 Jan; 27(1):50-2. PubMed ID: 15654280
[TBL] [Abstract][Full Text] [Related]
15. Mouse models of Down syndrome: gene content and consequences.
Gupta M; Dhanasekaran AR; Gardiner KJ
Mamm Genome; 2016 Dec; 27(11-12):538-555. PubMed ID: 27538963
[TBL] [Abstract][Full Text] [Related]
16. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
17. Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome.
Lyle R; Gehrig C; Neergaard-Henrichsen C; Deutsch S; Antonarakis SE
Genome Res; 2004 Jul; 14(7):1268-74. PubMed ID: 15231743
[TBL] [Abstract][Full Text] [Related]
18. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
19. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome.
Carmichael CL; Majewski IJ; Alexander WS; Metcalf D; Hilton DJ; Hewitt CA; Scott HS
Blood; 2009 Feb; 113(9):1929-37. PubMed ID: 19109561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
